Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... Processes and products based on,biomass and industrial ... in a wide range of applications such as,bioplastics. ... industrial,biotechnology in Germany will be held at the ... 2008) in Chicago, Illinois.,The panel runs from 10:45am ...
... be Produced in Changzhou Hi-Tech ... District, ... inactivated rabies animal vaccines was recently launched in,Changzhou National High-tech District, ... team of leading overseas scientists. It is,reported that it is the ...
... 25 Arpida Ltd.,(SWX: ARPN) today announced that Dr ... Officer. Dr Jurgen Raths commands extensive,knowledge in the commercialisation ... and has successfully built and lead the European,Critical Care ... for many years., At the Annual General Meeting ...
Cached Biology Technology:World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 2Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 2Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 4
(Date:7/30/2014)... Progress in developing robust therapies for spinal cord injury ... has been slow. A great deal has been learned ... factors and the environmental factors that regulate axon growth, ... resulted in clinically available therapeutics. Prof. Lemmon and his ... therapeutic bottleneck has many root causes, but a consensus ...
(Date:7/30/2014)... online today in the journal Scientific Reports , ... and Auroop Ganguly found that while global temperature is ... extremes. For instance, while each year,s average hottest and ... tend to fall within a wider range of potential ... observed. This means that even as overall temperatures rise, ...
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Menu secrets that can make you slim by design 2
... 2010 New evidence that genetics play a significant role ... can do everything right and still give birth too soon. ... for Maternal-Fetal Medicine (SMFM) meeting -- The Pregnancy Meeting -- ... fetus can make them susceptible to an inflammatory response that ...
... Himalayan mountains are thinning is not disputed. However, few ... causes. Lawrence Berkeley National Laboratory scientist Surabi Menon set ... blamed culpritgreenhouse gases, such as carbon dioxidefrom other particles ... Menon and her collaborators found that airborne black carbon ...
... could predict which patients with the lung-scarring disease known as ... an indicator that could one day influence their treatment, according ... Their findings, published online last week in PLoS One ... tissue, suggesting that IPF is in fact an immunologic disease. ...
Cached Biology News:New research shows genes of pregnant women and their fetuses can increase the risk of preterm labor 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Test could predict which idiopathic pulmonary fibrosis patients will become severely ill 2
Proline-serine-threonine phosphatase-interacting protein 2...
E2F2 protein...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: